embryonic stem cells escs pluripotent stem cells derived inner cell mass blastocyst earlystage preimplantation human embryos reach blastocyst stage days post fertilization time consist cells isolating inner cell mass embryoblast using immunosurgery results destruction blastocyst process raises ethical issues including whether embryos preimplantation stage moral considerations embryos postimplantation stage researchers currently focusing heavily therapeutic potential embryonic stem cells clinical use goal many potential uses include treatment diabetes heart cells studied used clinical therapies models genetic disorders cellulardna repair however adverse effects research clinical processes tumors unwanted immune responses also embryonic stem cells escs derived blastocyst stage early mammalian embryos distinguished ability differentiate embryonic cell type ability selfrenew traits makes valuable scientific medical fields escs normal karyotype maintain high telomerase activity exhibit remarkable longterm proliferative embryonic stem cells inner cell mass pluripotent meaning able differentiate generate primitive ectoderm ultimately differentiates gastrulation derivatives three primary germ layers ectoderm endoderm mesoderm germ layers generate cell types adult human body provided appropriate signals escs initially form precursor cells subsequently differentiate desired cell types pluripotency distinguishes embryonic stem cells adult stem cells multipotent produce limited number cell types defined conditions embryonic stem cells capable selfrenewing indefinitely undifferentiated state selfrenewal conditions must prevent cells clumping maintain environment supports unspecialized typically done lab media containing serum leukemia inhibitory factor serumfree media supplements two inhibitory drugs mek inhibitor inhibitor escs divide frequently due shortened phase cell cycle rapid cell division allows cells quickly grow number size important early embryo development escs cyclin cyclin e proteins involved transition always expressed high cyclindependent kinases promote cell cycle progression overactive part due downregulation retinoblastoma proteins inhibit transcription factor cell ready enter phase hyperphosphorylated inactivated escs leading continual expression proliferation changes result accelerated cycles cell division although high expression levels proproliferative proteins shortened phase linked maintenance escs grown serumfree conditions express hypophosphorylated active retinoblastoma proteins elongated despite difference cell cycle compared escs grown media containing serum cells similar pluripotent pluripotency factors nanog play role transcriptionally regulating embryonic stem cell due plasticity potentially unlimited capacity selfrenewal embryonic stem cell therapies proposed regenerative medicine tissue replacement injury disease pluripotent stem cells shown promise treating number varying conditions including limited spinal cord injuries age related macular degeneration diabetes neurodegenerative disorders parkinsons disease aids addition potential regenerative medicine embryonic stem cells provide possible alternative source tissueorgans serves possible solution donor shortage dilemma ethical controversies surrounding though see ethical debate section aside uses escs also used research early human development certain genetic disease vitro toxicology according article pnas human embryonic stem cells potential differentiate various cell types thus may useful source cells transplantation tissue tissue engineering use stem cells known importance order successfully engineer tissue cells used must able perform specific biological functions secretion cytokines signaling molecules interacting neighboring cells producing extracellular matrix correct organization stem cells demonstrates specific biological functions along able selfrenew differentiate one types specialized cells embryonic stem cells one sources considered use tissue use human embryonic stem cells opened many new possibilities tissue engineering however many hurdles must made human embryonic stem cell even utilized theorized embryonic stem cells altered evoke immune response implanted patient would revolutionary step tissue embryonic stem cells limited tissue engineering research focused differentiating escs variety cell types eventual use cell replacement therapies cell types currently developed include cardiomyocytes neurons hepatocytes bone marrow cells islet cells endothelial however derivation cell types escs without obstacles therefore research focused overcoming barriers example studies underway differentiate escs tissue specific cardiomyocytes eradicate immature properties distinguish adult besides becoming important alternative organ transplants escs also used field toxicology cellular screens uncover new chemical entities developed smallmolecule drugs studies shown cardiomyocytes derived escs validated vitro models test drug responses predict toxicity esc derived cardiomyocytes shown respond pharmacological stimuli hence used assess cardiotoxicity torsades de escderived hepatocytes also useful models could used preclinical stages drug discovery however development hepatocytes escs proven challenging hinders ability test drug metabolism therefore research focused establishing fully functional escderived hepatocytes stable phase ii enzyme several new studies started address concept modeling genetic disorders embryonic stem cells either genetically manipulating cells recently deriving diseased cell lines identified prenatal genetic diagnosis pgd modeling genetic disorders something accomplished stem cells approach may well prove valuable studying disorders fragilex syndrome cystic fibrosis genetic maladies reliable model system yury verlinsky russianamerican medical researcher specialized embryo cellular genetics genetic cytology developed prenatal diagnosis testing methods determine genetic chromosomal disorders month half earlier standard amniocentesis techniques used many pregnant women prospective parents especially couples history genetic abnormalities woman age risk genetically related disorders higher addition allowing parents select embryo without genetic disorders potential saving lives siblings already similar disorders diseases using cells disease free differentiated somatic cells es cells use different strategies dealing dna damage instance human foreskin fibroblasts one type somatic cell use nonhomologous end joining nhej error prone dna repair process primary pathway repairing doublestrand breaks dsbs cell cycle errorprone nature nhej tends produce mutations cells clonal descendants es cells use different strategy deal es cells give rise cell types organism including cells germ line mutations arising es cells due faulty dna repair serious problem differentiated somatic cells consequently robust mechanisms needed es cells repair dna damages accurately repair fails remove cells unrepaired dna damages thus mouse es cells predominantly use high fidelity homologous recombinational repair hrr repair type repair depends interaction two sister chromosomesverification needed formed phase present together phase cell cycle hrr accurately repair dsbs one sister chromosome using intact information sister chromosome cells phase cell cycle ie metaphasecell division prior next round replication one copy chromosome ie sister chromosomes arent present mouse es cells lack checkpoint undergo cell cycle arrest upon acquiring dna rather undergo programmed cell death apoptosis response dna apoptosis used failsafe strategy remove cells unrepaired dna damages order avoid mutation progression consistent strategy mouse es stem cells mutation frequency lower isogenic mouse somatic january phase clinical trials transplantation oligodendrocytes cell type brain spinal cord derived human escs spinal cordinjured individuals received approval us food drug administration fda marking worlds first human esc human study leading scientific advancement conducted hans keirstead colleagues university california irvine supported geron corporation menlo park ca founded michael west phd previous experiment shown improvement locomotor recovery spinal cordinjured rats delayed transplantation human escs pushed oligodendrocytic phase clinical study designed enroll eight ten paraplegics injuries longer two weeks trial begins since cells must injected scar tissue able form researchers emphasized injections expected fully cure patients restore mobility based results rodent trials researchers speculated restoration myelin sheathes increase mobility might occur first trial primarily designed test safety procedures everything went well hoped would lead future studies involve people severe trial put hold august due fda concerns regarding small number microscopic cysts found several treated rat models hold lifted july october researchers enrolled administered escs first patient shepherd center makers stem cell therapy geron corporation estimated would take several months stem cells replicate therapy evaluated success failure november geron announced halting trial dropping stem cell research financial reasons would continue monitor existing patients attempting find partner could continue biotime led ceo dr michael west acquired gerons stem cell assets stated intention restarting gerons embryonic stem cellbased clinical trial spinal cord injury biotime company asterias biotherapeutics nyse mkt ast granted million strategic partnership award california institute regenerative medicine cirm reinitiate worlds first embryonic stem cellbased human clinical trial spinal cord injury supported california public funds cirm largest funder stem cellrelated research development award provides funding asterias reinitiate clinical development subjects spinal cord injury expand clinical testing escalating doses target population intended future pivotal population cells derived human embryonic stem cells hescs contains oligodendrocyte progenitor cells opcs opcs mature derivatives called oligodendrocytes provide critical functional support nerve cells spinal cord brain asterias recently presented results phase clinical trial testing low dose patients neurologically complete thoracic spinal cord injury results showed successfully delivered injured spinal cord site patients followed years administration showed evidence serious adverse events associated cells detailed followup assessments including frequent neurological exams mris immune monitoring subjects one year posttransplantation showed evidence antibodybased cellular immune responses four five subjects serial mri scans performed throughout year followup period indicate reduced spinal cord cavitation may occurred may positive effects reducing spinal cord tissue deterioration unexpected neurological degeneration improvement five subjects trial evaluated international standards neurological classification spinal cord injury isncsci strategic partnership iii grant cirm provide funding asterias support next clinical trial subjects spinal cord injury asterias product development efforts refine scale manufacturing methods support laterstage trials eventually commercialization cirm funding conditional fda approval trial completion definitive agreement asterias cirm asterias continued progress toward achievement certain predefined project major concern possible transplantation escs patients therapies ability form tumors including safety issues prompted fda place hold first esc clinical trial however tumors observed main strategy enhance safety escs potential clinical use differentiate escs specific cell types eg neurons muscle liver cells reduced eliminated ability cause tumors following differentiation cells subjected sorting flow cytometry purification escs predicted inherently safer ips cells created genetically integrating viral vectors genetically modified genes cmyc linked cancer nonetheless escs express high levels ips inducing genes genes including myc essential esc selfrenewal potential strategies improve safety eliminating cmyc expression unlikely preserve cells stemness however nmyc lmyc identified induce ips cells instead cmyc similar later protocols induce pluripotency bypass problems completely using nonintegrating rna viral vectors sendai virus mrna transfection due nature embryonic stem cell research lot controversial opinions topic since harvesting embryonic stem cells usually necessitates destroying embryo cells obtained moral status embryo comes question people claim mass cells young achieve personhood embryo donated ivf clinic labs typically acquire embryos would otherwise go medical waste anyway opponents esc research claim embryo human life therefore destroying murder embryo must protected ethical view developed human vitro fertilization generates multiple embryos surplus embryos clinically used unsuitable implantation patient therefore may donated donor consent human embryonic stem cells derived donated embryos additionally also extracted cloned embryos created using cell patient donated egg process somatic cell nuclear inner cell mass cells interest blastocyst stage embryo separated trophectoderm cells would differentiate extraembryonic tissue immunosurgery process antibodies bound trophectoderm removed another solution mechanical dissection performed achieve separation resulting inner cell mass cells plated onto cells supply support inner cell mass cells attach expand form human embryonic cell line undifferentiated cells fed daily enzymatically mechanically separated every four seven days differentiation occur human embryonic stem cell line removed supporting cells form embryoid bodies cocultured serum containing necessary signals grafted threedimensional scaffold embryonic stem cells derived inner cell mass early embryo harvested donor mother animal martin evans matthew kaufman reported technique delays embryo implantation allowing inner cell mass increase process includes removing donor mothers ovaries dosing progesterone changing hormone environment causes embryos remain free uterus days intrauterine culture embryos harvested grown vitro culture inner cell mass forms egg cylinderlike structures dissociated single cells plated fibroblasts treated mitomycinc prevent fibroblast mitosis clonal cell lines created growing single cell evans kaufman showed cells grown cultures could form teratomas embryoid bodies differentiate vitro indicating cells gail martin derived cultured es cells differently removed embryos donor mother approximately hours copulation cultured overnight medium containing serum following day removed inner cell mass late blastocyst using microsurgery extracted inner cell mass cultured fibroblasts treated mitomycinc medium containing serum conditioned es cells approximately one week colonies cells grew cells grew culture demonstrated pluripotent characteristics demonstrated ability form teratomas differentiate vitro form embryoid bodies martin referred cells es known feeder cells provide leukemia inhibitory factor lif serum provides bone morphogenetic proteins bmps necessary prevent es cells factors extremely important efficiency deriving es cells furthermore demonstrated different mouse strains different efficiencies isolating es current uses mouse es cells include generation transgenic mice including knockout mice human treatment need patient specific pluripotent cells generation human es cells difficult faces ethical issues addition human es cell research many groups focused generation induced pluripotent stem cells ips august online edition nature scientific journal published letter dr robert lanza medical director advanced cell technology worcester stating team found way extract embryonic stem cells without destroying actual technical achievement would potentially enable scientists work new lines embryonic stem cells derived using public funding us federal funding time limited research using embryonic stem cell lines derived prior august march limitation human embryonic stem cells also derived somatic cell nuclear transfer approach also sometimes referred therapeutic cloning scnt bears similarity kinds cloning nuclei transferred somatic cell enucleated zygote however case scnt used produce embryonic stem cell lines lab living organisms via pregnancy therapeutic part name included hope scnt produced embryonic stem cells could clinical utility ips cell technology pioneered shinya yamanakas lab kyoto japan showed introduction four specific genes encoding transcription factors could convert adult cells pluripotent stem awarded nobel prize along sir john gurdon discovery mature cells reprogrammed become shown pluripotent stem cells highly similar embryonic stem cells induced delivery four factors cmyc differentiated utilizing four genes previously listed differentiated cells reprogrammed pluripotent stem cells allowing generation pluripotentembryonic stem cells without embryo morphology growth factors lab induced pluripotent cells equivalent embryonic stem cells leading cells known induced pluripotent stem cells ips observation observed mouse pluripotent stem cells originally performed human adult fibroblasts using four genes ethical concerns regarding embryonic stem cells typically derivation terminated embryos believed reprogramming ips cells may less controversial may enable generation patient specific es cell lines could potentially used cell replacement therapies addition allow generation es cell lines patients variety genetic diseases provide invaluable models study diseases however first indication ips cell technology rapid succession lead new cures used research team headed rudolf jaenisch whitehead institute biomedical research cambridge massachusetts cure mice sickle cell anemia reported science journals online edition december january californiabased company stemagen announced created first mature cloned human embryos single skin cells taken adults embryos harvested patient matching embryonic stem online edition nature medicine published study january stated human embryonic stem cells available federally funded research contaminated nonhuman molecules culture medium used grow common technique use mouse cells animal cells maintain pluripotency actively dividing stem cells problem discovered nonhuman sialic acid growth medium found compromise potential uses embryonic stem cells humans according scientists university california san however study published online edition lancet medical journal march detailed information new stem cell line derived human embryos completely cell serumfree conditions months undifferentiated proliferation cells demonstrated potential form derivatives three embryonic germ layers vitro teratomas properties also successfully maintained passages established stem cell muse cells multilineage differentiating stress enduring cell noncancerous pluripotent stem cell found discovered mari dezawa research muse cells reside connective tissue nearly every organ including umbilical cord bone marrow peripheral collectable commercially obtainable mesenchymal cells human fibroblasts bone marrowmesenchymal stem cells adiposederived stem muse cells able generate cells representative three germ layers single cell spontaneously cytokine induction expression pluripotency genes triploblastic differentiation selfrenewable generations muse cells undergo teratoma formation transplanted host environment vivo eradicating risk tumorigenesis unbridled cell httpsenwikipediaorgwikiembryonicstemcell